Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Travere TherapeuticsTVTX +1.96%61 Days Payable is 100.82 as of Jun. 2026, which is 91% below its 10-year median of 1,162.38. GuruFocus rates TVTX with a GF Score™ of 61/100 and a GF Value™ of $36.75 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 704 Biotechnology companies, Travere Therapeutics ranks better than 57.39% on this metric.
The historical rank and industry rank for Travere Therapeutics's Days Payable or its related term are showing as below:
TVTX'
s Days Payable Range Over the Past 10 Years
Min: 150.16 Med: 1162.38 Max: 1536.76
Current: 150.16
During the past 13 years, Travere Therapeutics's highest Days Payable was 1536.76. The lowest was 150.16. And the median was 1162.38.
TVTX's Days Payable is ranked better than 57.39% of 704
companies
in the Biotechnology industry
Industry Median: 110.01
vs TVTX: 150.16
Travere Therapeutics's Days Payable
declined
from Jun. 2025 (103.88) to Jun. 2026 (100.82).
It may suggest that Travere Therapeuticsaccelerated paying its suppliers.
The historical data trend for Travere Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Travere Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Travere Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Travere Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Travere Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Travere Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics (TVTX) has a Days Payable of 100.82 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Travere Therapeutics and its competitors. This is 91% below median its historical median of 1,162.38. Over the past decade, Travere Therapeutics' Days Payable has ranged from 150.16 to 1,536.76. According to the industry distribution chart, Travere Therapeutics ranks #300 out of 704 companies in the Biotechnology industry, placing it in the top 42.6%.
Is Travere Therapeutics' Days Payable too high?
Travere Therapeutics' current Days Payable of 100.82 is 91% below median its 10-year median of 1,162.38. Over the past 10 years, this metric has ranged from a low of 150.16 to a high of 1,536.76. The Biotechnology industry median Days Payable is 110.01. Travere Therapeutics' value of 100.82 is 8.4% below this industry median. Based on the distribution chart, Travere Therapeutics ranks #300 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Travere Therapeutics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Travere Therapeutics' Days Payable compare to ORKA and DNTH?
According to the Biotechnology industry distribution chart, Travere Therapeutics ranks #300 out of 704 companies for Days Payable. This puts Travere Therapeutics in the upper half of its industry. The industry median Days Payable is 110.01. Travere Therapeutics' value of 100.82 is 8.4% below this benchmark. Historically, Travere Therapeutics' own Days Payable has ranged from 150.16 to 1,536.76 over the past decade. While the company's 10-year median is 1,162.38 vs. the industry median of 110.01, Travere Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.01, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Travere Therapeutics's current Days Payable of 100.82 is 8.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Travere Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 110.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Travere Therapeutics's current Days Payable is 100.82, which is 91% below median its own 10-year median of 1,162.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Travere Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Travere Therapeutics (TVTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $36.75, compared to a current price of $65.71 — trading 78.8% above its estimated fair value. The current Days Payable is 100.82, which is 91% below median its 10-year median of 1,162.38 and 8.4% below the Biotechnology industry median of 110.01. Travere Therapeutics' overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Travere Therapeutics (TVTX), the current Days Payable is 100.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Travere Therapeutics (TVTX) Overvalued in 2026?
Based on GuruFocus' analysis, Travere Therapeutics stock appears to be overvalued.
The current stock price of $65.71 is trading 78.8% above its estimated GF Value™ of $36.75.
GuruFocus considers Travere Therapeutics to be Significantly Overvalued.
Key valuation signals for TVTX:
Days Payable: 100.82 (91% below median its 10-year median of 1,162.38)
GF Value™: $36.75 vs. price of $65.71 (78.8% above fair value)
Industry Position: 8.4% below the Biotechnology median (#300 of 704)
No single metric tells the full story. See the TVTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
61GF Score
Get the complete analysis for TVTX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TVTX has been successfully added to your 
